ADAM30通过激活组织蛋白酶D下调阿尔茨海默病中APP相关缺陷
ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease
摘要:
虽然几种ADAM(A解整合素样和金属蛋白酶)已被证明有助于淀粉样前体蛋白(APP)代谢,但参与这种代谢的金属蛋白酶的全谱仍有待建立。以金属蛋白酶基因为中心的转录组学分析揭示了ADAM 30表达减少50%,这与阿尔茨海默病大脑中的淀粉样蛋白负荷呈负相关。因此,在体外下调或上调ADAM 30的表达触发了A $β$肽水平的增加/减少,而生物学上无活性的ADAM 30(ADAM 30 mut)的表达不影响A $β$的分泌。蛋白质组学/基于细胞的实验表明,APP代谢的ADAM 30依赖性调节需要组织蛋白酶D(CTSD)激活和APP分选到溶酶体。因此,在阿尔茨海默样转基因小鼠中,神经元ADAM 30过表达降低神经元原代培养物中的A $β$ 42分泌、脑中的可溶性A $β$ 42和淀粉样斑块负荷水平,并伴随增强CTSD活性,最终挽救长时程增强。
英文摘要:
Although several ADAMs (A disintegrin-like and metalloproteases) have been shown to contribute to the amy-loid precursor protein (APP) metabolism, the full spectrum of metalloproteases involved in this metabolism remains to be established. Transcriptomic analyses centred on metalloprotease genes unraveled a 50% decrease in ADAM30 expression that inversely correlates with amyloid load in Alzheimer's disease brains. Accordingly, in vitro down-or up-regulation of ADAM30 expression triggered an increase/decrease in A$β$ peptides levels whereas expression of a biologically inactive ADAM30 (ADAM30 mut) did not affect A$β$ secretion. Proteomics/cell-based experiments showed that ADAM30-dependent regulation of APP metabolism required both cathepsin D (CTSD) activation and APP sorting to lysosomes. Accordingly, in Alzheimer-like transgenic mice, neuronal ADAM30 over-expression lowered A$β$42 secretion in neuron primary cultures, soluble A$β$42 and amyloid plaque load levels in the brain and concomitantly enhanced CTSD activity and finally rescued long term potentiation.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。